Life-Threatening Macrophage Activation Syndrome in Pregnancy: First Manifestation of SLE Induced by Parvovirus B19
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26115406 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Aleksandra Plavsic und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Allergy and Immunology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Macrophage Activation Syndrome, Parvovirus B19, Human, Parvoviridae Infections. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Macrophage activation syndrome (MAS) is a complex, life-threatening, hyperinflammatory condition occurring as a form of hemophagocytic lymphohistiocytosis (HLH), commonly associated with several autoimmune and autoinflammatory diseases, and certain infections such as Parvovirus B19 (P19V). The onset of systemic lupus erythematosus (SLE) presenting as MAS during pregnancy is uncommon, posing significant diagnostic and therapeutic challenges. We present a case of a 30-year-old woman at the 12th gestational week with fever, arthralgia, rash, cervical lymphadenopathy, cytopenia, and elevated liver enzyme. Bone marrow biopsy revealing hemophagocytosis, elevated ferritin and triglycerides, high interleukin-2, fever and cytopenia, confirmed the diagnosis of HLH. Further evaluation revealed the diagnosis of SLE. Treatment was initiated with intravenous immunoglobulin and corticosteroids. Given the deterioration in the patient’s clinical condition, a decision was made to terminate the pregnancy. She continued in the following months to receive SLE treatment with corticosteroids, cyclophosphamide, hydroxychloroquine, and later with mycophenolate mofetil due to the development of Class IV of lupus nephritis. P19V IgM antibodies were initially positive, later seroconverted to IgG, indicating that infection may have acted as a trigger for the onset of SLE and MAS development during pregnancy. The overlapping clinical features of P19V infection, SLE, and MAS pose significant diagnostic and therapeutic challenges. Early recognition and comprehensive diagnostic evaluation are crucial for the management of these conditions, especially during pregnancy, where both maternal outcomes are at risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinic for Allergy and Immunology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
- Clinic for Infectious and Tropical Diseases, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.
ORCID-Profile: Rada Miskovic, Zikica Jovicic, Aleksandra Dasic
Zitieren
APA
Plavsic, A., Miskovic, R., Jovanovic, D., Karic, U., Jovicic, Z., Radovic, S., Drazic, A., Dasic, A., & Arandjelovic, S. (2025). Life-Threatening Macrophage Activation Syndrome in Pregnancy: First Manifestation of SLE Induced by Parvovirus B19. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115406
Vancouver
Plavsic A, Miskovic R, Jovanovic D, Karic U, Jovicic Z, Radovic S, et al. Life-Threatening Macrophage Activation Syndrome in Pregnancy: First Manifestation of SLE Induced by Parvovirus B19. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115406
BibTeX
@article{Plavsic2025,
author = {Plavsic, Aleksandra and Miskovic, Rada and Jovanovic, Dragana and Karic, Uros and Jovicic, Zikica and Radovic, Sara and Drazic, Ana and Dasic, Aleksandra and Arandjelovic, Snezana},
title = {Life-Threatening Macrophage Activation Syndrome in Pregnancy: First Manifestation of SLE Induced by Parvovirus B19},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26115406}
}
EUVIMED